Literature DB >> 3935572

Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.

T Hidvégi, G Füst, E Rajnavölgyi, J Kulics, J Gergely.   

Abstract

Rabbit red blood cells (RaRBC, 3 x 10(7)/ml PBS) were incubated with different amounts of purified human C3 at 37 degrees for 30 min and washed twice in PBS. Different amounts of normal human serum containing 2 mM Mg2+ and 5 mM EGTA were added to the C3-treated and control RaRBC. The extent of lysis was measured after a further incubation at 37 degrees for 40 min. Enhanced lysis was observed with C3-treated RaRBC as compared to control cells. The enhancing effect was dependent on the dose of C3 used for the treatment of RaRBC. Investigation the kinetics of lysis, the lag phase was observed to be significantly shorter with the C3-treated than with the control RaRBC. No enhancement was found when RaRBC were pretreated with preformed C3b fragment. KSCN-treated C3 (C3b-like C3), however, had a lysis-enhancing effect. These results suggest that noncovalently bound C3 molecules may have a role in the initiation and/or maintenance of the alternative pathway activation on activator cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3935572      PMCID: PMC1453793     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

1.  Interaction between the third complement protein and cell surface macromolecules.

Authors:  S K Law; R P Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

Review 2.  The role of antibody in the activation of the alternative complement pathway.

Authors:  W D Ratnoff; D T Fearon; K F Austen
Journal:  Springer Semin Immunopathol       Date:  1983

3.  The covalent-binding reaction of complement component C3.

Authors:  R B Sim; T M Twose; D S Paterson; E Sim
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

4.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

5.  C3c and C3d fragments of human C3 bind myeloma IgG1 and IgG3 proteins.

Authors:  A Hautanen; A Sarnesto; J Keski-Oja; I Seppälä
Journal:  Immunol Lett       Date:  1982-11       Impact factor: 3.685

6.  [Selective binding in vitro of a modified form of the C3 component of complement to human erythrocytes].

Authors:  C Micouin; E Hudry-Clergeon; B Roussel; N Battail; A Tournoud; M G Colomb
Journal:  Ann Immunol (Paris)       Date:  1983 Mar-Apr

7.  The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.

Authors:  J Mann; R O'Brien; M K Hostetter; C A Alper; F S Rosen; B M Babior
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

8.  C3b binding immune complexes and immunoconglutinins in human sera. Detection by enzyme-linked immunosorbent assay (ELISA).

Authors:  A Hautanen; E Linder
Journal:  J Immunol Methods       Date:  1979       Impact factor: 2.303

9.  Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.

Authors:  D T Fearon; K F Austen
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins.

Authors:  R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.